A+ A-


Psychoactive substances, users and markets - Recent trends (2019-2020)



Tendances n° 141, OFDT, 8 p.
December 2020

Since 1999, the Emerging Trends and New Drugs (TREND) scheme of the OFDT has been monitoring emerging phenomena and developments in the field of drugs. It focuses on populations with a high level of psychoactive substance consumption and is based on qualitative data collected by the network of TREND sites located in eight metropolitan areas. The trends presented in Tendances No. 141 cover the year 2019 and the first two months of 2020.

The issue looks first at the continuing deterioration in the socio-sanitary situations of the most vulnerable users, then at the spread of use in techno party settings, particularly of ketamine and MDMA/ecstasy, and the issue of access to harm reduction. The second part deals with changes in supply, especially the development of home deliveries, and the third part deals with the use of psychoactive products that marked the year 2019.

Authors : Clément Gérome, Michel Gandilhon

Download the PDF file (454 Ko)














Drugs in Europe

2023 EMCDDA European Drug Report

The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national data across these themes and key harm-reduction interventions. This report is based on information provided to the EMCDDA by the EU Member States, the candidate country Türkiye, and Norway, in an annual reporting process.

  Statistical Bulletin 2023

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format.

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.